+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Humira

  • ID: 4775308
  • Report
  • August 2018
  • Region: Global
  • 94 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Humira (adalimumab; AbbVie/Eisai) is a recombinant human immunoglobulin G1 monoclonal antibody that acts as a tumor necrosis factor (TNF) inhibitor. In the US and EU, Humira is marketed by AbbVie, while in Japan, Abbott partnered with Eisai in 1999 to commercialize and develop the biologic.

Humira is approved for use in several autoimmune indications, namely rheumatoid arthritis, psoriatic arthritis, axial Spondyloarthritis, Behçet’s syndrome, ulcerative colitis, juvenile idiopathic arthritis, Crohn’s disease, hidradenitis suppurativa, non-infectious uveitis, and plaque psoriasis
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Humira: Crohn's disease
Humira: Axial spondyloarthritis
Humira: Rheumatoid arthritis
Humira: Psoriatic arthritis
Humira: Ulcerative colitis
Humira: Psoriasis

LIST OF FIGURES
Figure 1: Humira for Crohn’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of Humira in Crohn’s disease
Figure 3: The authors drug assessment summary of Humira in Crohn’s disease
Figure 4: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Humira for axial spondyloarthritis – SWOT analysis
Figure 6: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 7: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 8: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 9: Humira for rheumatoid arthritis – SWOT analysis
Figure 10: The authors drug assessment summary of Humira in rheumatoid arthritis
Figure 11: The authors drug assessment summary of Humira in rheumatoid arthritis
Figure 12: Humira for psoriatic arthritis – SWOT analysis
Figure 13: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 14: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 15: Humira for ulcerative colitis – SWOT analysis
Figure 16: The authors drug assessment summary of Humira for ulcerative colitis
Figure 17: The authors drug assessment summary of Humira for ulcerative colitis
Figure 18: Humira for psoriasis – SWOT analysis
Figure 19: The authors drug assessment summary of Humira in psoriasis
Figure 20: The authors drug assessment summary of Humira in psoriasis

LIST OF TABLES
Table 1: Humira drug profile
Table 2: Humira pivotal trial data in adult Crohn’s disease
Table 3: Humira pivotal trial data in pediatric Crohn’s disease
Table 4: Humira ongoing trials in Crohn’s disease
Table 5: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 6: Humira drug profile
Table 7: Humira pivotal trial data in axial spondyloarthritis
Table 8: Humira late-phase trial data in axial spondyloarthritis
Table 9: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Table 10: Humira drug profile
Table 11: Humira pivotal trial data in rheumatoid arthritis
Table 12: Humira late-phase trial data in rheumatoid arthritis
Table 13: Humira drug profile
Table 14: Humira pivotal trial data in psoriatic arthritis
Table 15: Humira late-phase trial data in psoriatic arthritis
Table 16: Humira drug profile
Table 17: Humira pivotal trial data in ulcerative colitis
Table 18: Humira ongoing late-phase trials in ulcerative colitis
Table 19: Humira drug profile
Table 20: Humira pivotal trial data in adult psoriasis
Table 21: Humira pivotal trial data in pediatric psoriasis
Table 22: Humira late-phase trial data in psoriasis
Table 23: Humira ongoing late-phase clinical trials in psoriasis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll